文献速递慢性肾脏病遗传性与小管间质肾病

常染色体显性多囊肾病影响量表的开发:一种新的健康相关生活质量工具

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
PubMed 文献 · Am J Kidney Dis · 2017-11-14

本研究开发了用于评估常染色体显性多囊肾病(ADPKD)患者健康相关生活质量(HRQoL)的自填患者报告结局(PRO)问卷ADPKD影响量表(ADPKD-IS)。通过专家和患者焦点小组生成内容,并对1674例成人ADPKD患者(285例焦点小组、15例访谈、1374例测量评估)进行信效度检验。结果显示ADPKD-IS包含14个条目(躯体、情绪、疲劳3个领域)加4个额外问题,信度和效度得到支持。

要点

  • ADPKD-IS是首个针对ADPKD患者HRQoL的标准化PRO工具。
  • 量表包含14个条目覆盖躯体、情绪、疲劳3领域,另有4个额外问题。
  • 在1374例患者中验证了内部一致性、重测信度及内容与结构效度。

核心结论

  • ADPKD-IS是一种以患者为中心的新工具,能可靠且有效地标准化评估ADPKD患者的HRQoL和总体疾病负担。

研究设计与样本

  • 通过临床专家和患者焦点小组讨论生成问卷内容,并对ADPKD患者施测以评估信度和效度。
  • 共1674例成人ADPKD患者参与:285例参与焦点小组生成内容,15例参与访谈优化问卷,1374例参与评估测量性能。

主要发现

  • 开发出ADPKD影响量表(ADPKD-IS),包含14个条目代表3个概念领域(躯体、情绪、疲劳)加4个额外问题。
  • 量表的信度(内部一致性和重测一致性)和效度(内容和结构效度)得到支持。

临床怎么用

  • ADPKD-IS可用于标准化评估ADPKD患者的HRQoL和疾病负担,辅助临床决策。

局限性

  • 需要更多临床使用数据以进行反应度测试。
  • ADPKD相关疼痛等复杂概念及其对HRQoL的影响需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of autosomal dominant polycystic kidney disease (ADPKD) on health-related quality of life (HRQoL) is not well understood due to a lack of instruments specific to the condition. STUDY DESIGN: Content for a new self-administered patient-reported outcome (PRO) questionnaire to assess ADPKD-related HRQoL was developed through clinical expert and patient focus group discussions. The new PRO instrument was administered to study patients with ADPKD to evaluate its reliability and validity. SETTING & PARTICIPANTS: 1,674 adult patients with ADPKD participated in this research: 285 patients in focus groups to generate questionnaire content, 15 patients in debriefing interviews to refine the PRO questionnaire, and 1,374 patients to assess the performance and measurement properties of the PRO questionnaire. OUTCOME: A new PRO questionnaire. RESULTS: The ADPKD Impact Scale (ADPKD-IS), consisting of 14 items representing 3 conceptual domains (physical, emotional, and fatigue) plus 4 additional questions, was developed. The instrument's reliability (regarding internal consistency and test-retest consistency) and validity (content and construct) were supported. LIMITATIONS: Need for more responsiveness testing when more data from clinical use become available over time. Complex concepts such as ADPKD-related pain and impact on a patient's HRQoL need further evaluation. CONCLUSIONS: The ADPKD-IS is a new patient-centric tool that reliably and validly provides a standardized method for assessing HRQoL and overall disease burden in patients with ADPKD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Oberdhan D, Cole JC, Krasa HB, et al. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Am J Kidney Dis. 2017. PMID: 29150246. doi:10.1053/j.ajkd.2017.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。